Trials / Completed
CompletedNCT02808442
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UCART19 |
Timeline
- Start date
- 2016-06-03
- Primary completion
- 2020-09-17
- Completion
- 2020-11-04
- First posted
- 2016-06-21
- Last updated
- 2021-10-08
Locations
6 sites across 4 countries: United States, France, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02808442. Inclusion in this directory is not an endorsement.